Business Wire - September 20, 2002

"Because of our low cost threshold, (WDI is able to deliver these and other unit tests at less than $1.00 USD for Point of Care testing in emerging markets), we believe this makes us a leader in providing quality health care products at affordable prices to combat the spread of HIV/AIDS, and other infectious diseases such as Malaria, Dengue Fever, Tuberculosis and Hepatitis. WDI's Smart Check HIV rapid test is one of the few Point of Care HIV rapid tests to hold FDA Tier 1 Nation Status, enabling it to qualify through local government evaluations and approvals for sale in numerous countries throughout the world that include Jamaica, Trinidad, Nicaragua, Argentina, Nepal, Malaysia, Uganda, Zambia, Nigeria and South Africa.

"The expanding role of government approvals and purchase orders on a country by country basis has favorably impacted WDI's ability to gain recognition and new business from non-governmental organizations, ('NGO's'), in the private sector such as NGO Clinics, private for profit clinics and physician offices. WDI currently has pending approvals in Brazil for its Smart Check HIV rapid test, along with several other Point of Care tests, and is confident that it will commence business in Brazil this calendar year. In addition, WDI's wholly owned subsidiary World Diagnostics PTY SA, based in Johannesburg, South Africa, is well positioned to expand, based on the growing demand and acceptance in central and sub-Saharan African for rapid P.O.C infectious disease tests," commented Ken Peters, President and Founder of WDI.

About World Diagnostics, Inc. and GLOBALeMED.com

WDI is an innovative leader in providing a wide range of medical diagnostic and laboratory products worldwide, offering the most comprehensive resource for most medical diagnostic tests and laboratory products on a global basis. WDI provides a network of conventional and dedicated distribution channels for accessing international markets, and a simplified option, through its GLOBALeMED e-commerce platform, for purchasing medical laboratory and healthcare products on line.

WDI's marketing platform of distributors and GLOBALeMED partners covers 85 countries, affording professional users easy and unlimited access to critical technical data and information, training aids and online customer support. It is among the most comprehensive resources available for most medical diagnostic tests and laboratory products, currently comprising about 1,000 WDI-branded and numerous other products sold through distributors and directly to medical professionals, hospitals, physician offices, clinical laboratories, and retail drug stores. WDI's GLOBALeMED website is the only multicultural, multilingual, medical information-based website of its kind, generating new business leads daily and convenient transactional options, through conventional distribution or e-commerce options and contributing to WDI's growing worldwide customer base and name recognition.

WDI's vision is to be the premier resource for supplying diagnostic tests and allied medical laboratory products for the $5 billion emerging nation global marketplace. WDI is aggressively expanding its business and brand name through its distribution network and its GLOBALeMED e-commerce platform, which can be accessed at either www.worlddiagnostics.com or www.globalemed.com. WDI's GLOBALeMED website is the leading multicultural, multilingual, medical information-based website delivering efficient access to modern medical technology on a cost-effective basis. WDI has built substantial inroads and assets in the form of licenses and registrations for its products in numerous countries.

Except for historical matters contained herein, the matters discussed in this press release are forward-looking statements and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the assumptions and involve risk and uncertainties, which may affect World Diagnostics, Inc.'s business and prospects and cause actual results to differ materially from these forward-looking statements.

CONTACT: World Diagnostics, Inc.

Barry Peters, 310/234-9535

BPeters@worlddiagnostics.com

SOURCE: World Diagnostics, Inc.

020920
BW020904

Copyright © 2002 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .